The idea of synthetic biology – using computers, rather than trial and error, to rationally design drugs – has been around for years. But Woburn, Mass.-based Abpro is taking it to the next level with rationally designed antibodies using its Diversimmune platform. Labor intensive steps that used to take two to three years can now be done using bioinformatics that reduce the design time down to less than two months. Read More
With just one month to go before biopharma draws the curtains on a year that has seen its fair share of lows for the sector, it received an early Christmas present following Donald Trump's unexpected victory in the presidential election. Share values of drug developers have soared in the wake of the result because it came with the removal, at least for now, of fears that drug-pricing policy issues will be high on the political agenda going forward. Read More
